Study on novel therapeutic targets: PAIP1_HUMAN (G10605)

Target Name: PAIP1

NCBI ID: G10605

PAIP1

Study on novel therapeutic targets: PAIP1_HUMAN

Parkinson's disease is a common neurodegenerative disease characterized by decreased movement, muscle stiffness, and bradykinesia. It is one of the most common neurodegenerative diseases of the nervous system, and its incidence is increasing as the population ages. At present, the treatment of Parkinson's disease mainly includes drug treatment and non-drug treatment. Although pharmacotherapy has made significant progress in the treatment of Parkinson's disease, many unmet clinical needs remain. Therefore, the study of novel therapeutic targets has high clinical prospects.

Mechanism of action of PAIP1_HUMAN

PAIP1 (Parkinson's disease-associated protein 1) is a family membrane protein whose expression is upregulated in patients with Parkinson's disease. Its functions are mainly reflected in the following aspects:

1. Regulate neuronal activity

PAIP1 plays a key role in neuronal activity. Research shows that PAIP1 can affect the excitability balance of neurons, reduce the probability of over-excitation, and thereby maintain the homeostasis of neuronal activity. In addition, PAIP1 can also affect the apoptosis of neurons, prevent excessive growth and death of neurons, thereby delaying the development of Parkinson's disease.

2. Regulate muscle contraction

PAIP1 also plays an important role in muscle contraction. It can affect the contractility and frequency of muscle cells, thereby regulating the amplitude and speed of muscle contraction. In patients with Parkinson's disease, abnormal function of PAIP1 leads to muscle stiffness and reduced movement, which is also an important pathogenesis of the disease.

3. Participate in neurotransmitter regulation

PAIP1 also plays a key role in neurotransmitter regulation. It can bind to neurotransmitters and affect the release and reuptake of neurotransmitters, thereby affecting the function of the nervous system. Research shows that the combination of PAIP1 with neurotransmitters such as dopamine and acetylcholine may be closely related to the onset and development of Parkinson's disease.

4. Molecular mechanisms involved in Parkinson???s disease-related diseases

PAIP1 is related to Parkinson's disease-related diseases, such as neurodegenerative diseases, neuropsychiatric diseases, etc. For example, some studies have found that PAIP1 is closely related to neuronal apoptosis, neuronal synapse loss and other phenomena in patients with Parkinson's disease. In addition, PAIP1 also has a certain correlation with genes related to Parkinson's disease, such as SNCA, CAI and other genes.

Clinical value of PAIP1_HUMAN

As a new therapeutic target, PAIP1 has high value in the treatment of Parkinson's disease. First of all, PAIP1 has good tissue compatibility and will not cause damage to normal tissues of the human body, reducing the difficulty and risk of surgical operations. Secondly, PAIP1, as a molecular target, can be used as an effective target for drug research to screen out specific drugs with anti-Parkinson's disease effects, thereby improving the clinical efficacy of the drug.

Detection method of PAIP1_HUMAN

For patients with Parkinson's disease, detecting the expression level of PAIP1 has high clinical value. Commonly used detection methods include: Western blot, immunofluorescence staining, enzyme-linked immunosorbent assay (ELISA), etc. Western blot is a commonly used method to detect protein expression. By detecting the expression level of the target protein in the tissue, it can reflect the functional status of the protein in the tissue. Immunofluorescence staining is a method to directly observe the expression of target proteins in tissues, with high tissue resolution and expression levels. Enzyme-linked immunosorbent assay (ELISA) is a method for detecting protein expression and activity. It can detect the expression levels of multiple proteins at the same time, providing more options for research on therapeutic targets for Parkinson's disease.

Clinical application prospects of PAIP1_HUMAN

As a new therapeutic target, PAIP1 has high value in the treatment of Parkinson's disease. By studying the functional mechanism of PAIP1, we can reveal the molecular mechanisms related to Parkinson's disease and provide new ideas and methods for the treatment of Parkinson's disease. In addition, PAIP1 can also be used as a target for drug research to provide more clinically valuable therapeutic targets for patients with Parkinson's disease. With the continuous development of research technology, PAIP1, as a new therapeutic target, will bring more hope for the treatment of Parkinson's disease.

Protein Name: Poly(A) Binding Protein Interacting Protein 1

Functions: Acts as a coactivator in the regulation of translation initiation of poly(A)-containing mRNAs. Its stimulatory activity on translation is mediated via its action on PABPC1. Competes with PAIP2 for binding to PABPC1. Its association with EIF4A and PABPC1 may potentiate contacts between mRNA termini. May also be involved in translationally coupled mRNA turnover. Implicated with other RNA-binding proteins in the cytoplasmic deadenylation/translational and decay interplay of the FOS mRNA mediated by the major coding-region determinant of instability (mCRD) domain

The "PAIP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAIP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets